… III trial showed that the addition of ramucirumab to erlotinib … as firstline treatment of EGFR
mutation-positive advanced … , double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019…

… of treatment of metastatic NSCLC, as well small-cell lung … received either nivolumab or
placebo and the median OS was … Ramucirumab in combination with erlotinib showed a slightly …

… the addition of ramucirumab may improve PFS in patients with or without liver metastases at
… Especially, in the ARTEMIS-CTONG 1509 study, bevacizumab in combination with erlotinib …

… comparing with standard chemotherapy for the first line of metastatic … Similarly, the combination
of ramucirumab with erlotinib … mutation-positive non-small-cell lung cancer (EURTAC): a …

… in a randomized, double-blind, phase 3 FLAURA study [7]. … line treatment for EGFR
mutation-positive advanced or metastatic … A randomized phase 3 trial of ramucirumab plus …

… trial in China, a double-blind, head-to-head phase III study … T790M mutation-positive
advanced NSCLC patients treated with … Ramucirumab in combination with erlotinib significantly …

… They were ranked the top two treatments for patients with brain metastasis. Better … erlotinib
and ramucirumab showed a significantly improved PFS of 19.4 months in the RELAY trial…

… patients, have demonstrated PFS benefit of erlotinib plus … On the other side, treatment of
osimertinib plus ramucirumab … This has been observed in the NEJ 026 and RELAY studies in …

… 3 RELAY trial was designed to compare ramucirumab plus erlotinib and erlotinib alone and
ramucirumab plus erlotinib showed superior PFS in patients with EGFR-mutated metastatic …

… in 16% of patients versus 13% in the placebo group (16). … such as erlotinib plus ramucirumab
or erlotinib plus bevacizumab have … II multicenter study has analyzed toxicity in 381 patients …